Ani Pharmaceuticals (ANIP) Accounts Payables (2010 - 2026)

Ani Pharmaceuticals has disclosed Accounts Payables across 17 years of filings, most recently posting $73.8 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 35.3% year-over-year to $73.8 million; the TTM figure through Jun 2026 stood at $73.8 million (up 35.3% YoY), while the FY2025 annual figure was $62.6 million, up 37.08% from the prior year.
• Accounts Payables came in at $73.8 million for Q2 2026 at Ani Pharmaceuticals, up from $69.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $73.8 million in Q2 2026 to a low of $19.0 million in Q3 2022.
• Average Accounts Payables over 5 years is $45.5 million, with a median of $47.2 million recorded in 2024.
• Year-over-year, Accounts Payables surged 113.0% in 2022 and climbed 3.13% in 2023.
• Over 5 years, Accounts Payables stood at $29.3 million in 2022, then climbed by 25.18% to $36.7 million in 2023, then gained by 24.46% to $45.7 million in 2024, then jumped by 37.08% to $62.6 million in 2025, then climbed by 17.97% to $73.8 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $73.8 million in Q2 2026, $69.7 million in Q1 2026, and $62.6 million in Q4 2025.